An updated edition of the Feb. 20, 2026, article. Genomics involves a thorough study of genomes (an organism’s complete set of deoxyribonucleic acid or DNA). It involves understanding how genes ...

With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has ...

Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Biotech company Crispr Therapeutics Ag (NASDAQ:CRSP) shares are up 16% over the past 12 months.

There are plenty of reasons, though, to be bullish on the stock, not the least of which is its improved cash position. The ...

However, there is one key reason the stock could still deliver outstanding returns over the long run: Its pipeline could help ...

CRISPR recently raised nearly $600 million through a private offering, which weighed down its share price. The company has an approved therapy in Casgevy, but its business remains deeply unprofitable.

Alphabet has a massive AI tailwind and a potential gold mine with Waymo. Nvidia should remain the dominant player in AI chips for years to come. ServiceNow could be on track to become a $1 trillion ...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its ...